Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07591246

Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction

females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Polycystic Ovary Syndrome Adnexal Diseases Cysts Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Neoplasms Non-Alcoholic Fatty Pancreatic Disease Ovarian Cysts Ovarian Diseases Subclinical hypothyroïdism Urogenital Diseases

Age range

20 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

About this study

females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism) will be divided to groups (twenty female for the group). groups will be treated with levothyroxine and metformin, but one of these groups will perform aerobic treadmill walking.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PCOS
  • fattty pancrease (non-alcoholic)
  • subclinical hypothyroid (signifcant with thyroid stimauted horomone more than 10 mIU/L) and normal non-disordered free thyroxine horomones

Exclusion criteria

  • cardiac disesase
  • renal diseases
  • respiratory disease

Treatment and study plan

physical exercise program

Behavioral

twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily twotimes of 500-mg metformin, and these females will perform 50 minutes of aerobic treadmill walking hrice weekly for six month.

Usual Care

Other

twenty females of polycystic ovary syndromes may complain fatty pancreaetic disorder and thyroid hypofunctions (subclinical hypothyroidism)will be treated with daily dose of levothyroxine in addition to daily two times of 500-mg metformin for six month.

Primary outcomes

  1. Dehydroepiandrosterone

    Time frame: it will be measured after 6 months

    it is a hormone involved in synthesis of sex hormones

Secondary outcomes

  1. ratio of leutinzing hromone to hormone of follicels stimulatting hormones

    Time frame: it will be measured after 6 months

    this ration express level of sex hormone

  2. testesterone

    Time frame: it will be measured after 6 months

    it is a sex horomone

  3. body mass index

    Time frame: it will be measured after 6 months

    it will be assessed on empty stomach and bladder

  4. waist circumference

    Time frame: it will be measured after 6 months

    it will be assessed on umblical levels

  5. blood gluocose

    Time frame: it will be measured after 6 months

    it will be assessed in fasting status

  6. glycated hemoglubin

    Time frame: it will be measured after 6 months

    it is an indiactor for longterm satus of blood gloucose

  7. insulin

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

  8. thyroid stimualtined horomone

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

  9. triglyceridess

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

  10. low densitiy liopporotein

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

  11. cholesteroll

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

  12. high densitiy lipoporteins

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

  13. alanine transaminase

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

  14. aspartatte transaminase

    Time frame: it will be measured after 6 months

    it will be assessed in plasma

Study contacts

Contact information is provided by the study sponsor or research team.

Ali MA Ismail, lecturer

CONTACT

[email protected]

01005154209

ali mohamed

CONTACT

[email protected]

01031321109

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 15, 2026
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.